Plain-English translation of NCT01851642 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers at the University of Florida are studying how two genetic lung diseases—alpha-1 antitrypsin deficiency and cystic fibrosis—affect a type of immune cell called a macrophage that normally helps protect and repair the lungs. Scientists believe these diseases may prevent macrophages from working properly, which could explain why lung damage happens and gets worse over time. This study will compare lung function and immune cell behavior in people with these conditions to people without them.
Currently, doctors thought lung disease in alpha-1 antitrypsin deficiency was simply caused by not having enough of a protective protein. However, new research suggests the real problem may be that immune cells stop working correctly. Understanding this could lead to better treatments that help these immune cells function as they should.
You likely qualify if…
You likely don't qualify if…
At each study visit, you will have a brief physical exam, give a blood sample, and take a breathing test (using an inhaler) to measure how well your lungs work. The study involves comparing how your immune cells respond to lung disease, so these visits will be repeated over time. The exact number of visits and duration will depend on the study design, but all testing is non-invasive and happens in a clinic setting.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States
Sponsor
University of Florida
Enrollment target
~220 participants
Started
August 2007
Primary completion
July 2032
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Allison E. Faunce, B.A.
University of Florida, College of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.